Genagon Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 11

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.06M

  • Investors
  • 7

Genagon Therapeutics General Information

Description

Developer of bio-pharmaceuticals products designed to increase response rates in immuno-oncology. The company develops a platform helping to identify pathways in immune cells, discover a mechanism that cancers use to inhibit the innate immune system, and offer treatment for oncology and inflammatory diseases, providing the healthcare sector with new discoveries of unstudied proteins.

Contact Information

Website
www.genagon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Nanna Svartz Väg 2
  • 171 65 Solna
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genagon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 25-Mar-2021 $2.06M 00.00 Completed Generating Revenue
3. Grant 14-Mar-2017 000.00 00000 Completed Generating Revenue
2. Seed Round 26-Jan-2016 $235K $235K Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2015 Completed Startup
To view Genagon Therapeutics’s complete valuation and funding history, request access »

Genagon Therapeutics Patents

Genagon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202111640-D0 Polypeptides Inactive 13-Aug-2021
GB-202111639-D0 Therapeutic agents Inactive 13-Aug-2021
GB-201804531-D0 Antigen binding proteins Inactive 21-Mar-2018 000000000
GB-201700567-D0 Therapeutic agents Inactive 12-Jan-2017 000000000
US-11406665-B2 Therapeutic peptides that target tgf-beta interaction Active 12-Jan-2017 A61K35/17 00
To view Genagon Therapeutics’s complete patent history, request access »

Genagon Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Moa Fransson Ph.D Chief Executive Officer
Andries Blokzijl Co-Founder, Board Member & Scientific Advisor
Päivi Rosti Co-Founder
Simon Fredriksson Ph.D Co-Founder & Board Member
Claes Post Ph.D Ledamot
You’re viewing 5 of 6 executive team members. Get the full list »

Genagon Therapeutics Board Members (6)

Name Representing Role Since
Johan Lund Ph.D Self Board Member 000 0000
Karin von Wachenfeldt Ph.D Self Board Member 000 0000
Richard Åhlberg Ph.D Genagon Therapeutics Board Member 000 0000
Simon Fredriksson Ph.D Self Co-Founder & Board Member 000 0000
Svein Arild Mathisen Genagon Therapeutics Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Genagon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genagon Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Colibri Ventures Venture Capital Minority 000 0000 000000 0
Phase2Phase Biopharma Other Minority 000 0000 000000 0
Vinnova Government 000 0000 000000 0
Almi Invest Venture Capital Minority 000 0000 000000 0
Beijer Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »